Ovarian cancer (OC) remains a major clinical challenge because doctors often diagnose it at advanced stages. At this point, tumor heterogeneity and chemoresistance significantly impact survival rates. However, ovarian cancer organoids derived from ascites now offer a promising way to predict patient responses. These patient-derived organoids (PDOs) mimic the biological complexity of the parental tumor. Consequently, they provide a "living biobank" for precise drug testing.

Researchers recently achieved an 86.2% success rate in establishing these organoid models. Furthermore, whole-exome sequencing confirmed that the PDOs maintained the genomic features of the original cancer. The models accurately predicted how patients would respond to cisplatin and PARP inhibitors during their clinical treatment. This high level of fidelity makes them an ideal platform for personalized oncology.

Targeting Stem Cells in Ovarian Cancer Organoids

One of the most exciting findings involves the oncolytic virus OH2. This modified herpes simplex virus 2 directly kills cancer cells, even in cisplatin-resistant cases. Additionally, combining OH2 with cisplatin significantly reduced the CD44+ cancer stem cell population. Since these stem cells often drive recurrence, this combination offers a novel strategy to overcome resistance. Therefore, using PDOs for individualized testing could drastically improve clinical outcomes for ovarian cancer patients.

What are the success rates for establishing ascites-derived organoids?

Current research shows a high success rate of approximately 86.2%, allowing for reliable patient-specific modeling and drug sensitivity testing within a clinically relevant timeframe.

How does the OH2 virus help in treating ovarian cancer?

The OH2 virus acts as an oncolytic agent that directly kills cancer cells. Notably, it works synergistically with cisplatin to target and reduce the subpopulation of cancer stem cells that typically cause drug resistance.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Zhang X et al. Targeting cancer stem cells predicts response and reverses chemoresistance in ascites-derived ovarian cancer organoids. BMC Med. 2026 Feb 24. doi: 10.1186/s12916-026-04730-1. PMID: 41731502.

Nanki K et al. Patient-derived ovarian cancer organoids mimic parental tumor biology and predict drug responses. Nature Communications. 2020;11:4211.

Zhang B et al. Oncolytic herpes simplex virus 2 (OH2) for cancer therapy. Frontiers in Oncology. 2021;11:665555.